Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.
Oncocyte’s flagship products include:
- DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
- DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
- VitaGraft™: A blood-based solid organ transplantation monitoring test.
- GraftAssure™: A research-use-only monitoring test for solid organ transplantation.
The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.
Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.
Oncocyte Corporation (NYSE American: OCX) will participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2020, for 1-on-1 meetings. The company's mission is to enhance cancer care through molecular diagnostics with tools like DetermaRx, a test for early-stage lung cancer patients to identify recurrence risk, and DetermaIO, aimed at predicting immunotherapy responses. These innovations seek to improve patient outcomes by providing critical information at key decision points in cancer treatment.
Oncocyte Corporation (OCX) presented data on its DetermaIO™ test at the AMP 2020 Virtual Conference. This CLIA validated test utilizes real-time PCR to assess 27 genes, predicting responses to immune checkpoint inhibitors in non-small cell lung cancer and triple-negative breast cancer. Data show DetermaIO requires as little as 2mm2 of tissue, significantly less than other tests. This advancement may increase patient eligibility for immunotherapy and improve clinical decision-making. Oncocyte aims to launch DetermaIO for clinical use, enhancing cancer diagnosis and therapy options.
Oncocyte Corporation (NYSE American: OCX) reported significant progress in Q3 2020, achieving its first Medicare revenues for DetermaRx™ after receiving final CMS pricing. The test volume for DetermaRx more than doubled from the previous quarter, and the company anticipates near-term revenue from DetermaIO™ in checkpoint inhibitor trials. The collaboration with Chronix on TheraSure™-CNI MONITOR is expected to enhance revenue opportunities. However, the company reported a net loss of $6.8 million. With cash reserves of $10.7 million, Oncocyte aims for growth across its four revenue engines going forward.
Oncocyte Corporation (NYSE American: OCX) has announced plans to present data on its DetermaIO™ test at the Society for Immunotherapy of Cancer (SITC) 2020 Virtual Conference. This test aims to identify effective therapeutic options for patients with immune checkpoint inhibitor (ICI) resistance, particularly in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The findings suggest DetermaIO could help predict patient responses to ICIs, addressing a critical need in the growing $3B ICI therapy selection testing market.
Oncocyte Corporation (NYSE American: OCX) announced it will release its third-quarter financial results on November 12, 2020, after market close. A conference call will follow at 4:30 pm ET to discuss the results and recent corporate developments. Oncocyte focuses on molecular diagnostics to enhance cancer care through tests like DetermaRx for lung cancer recurrence risk and DetermaIO for immunotherapy responses. The company aims to improve treatment outcomes and drive revenue growth through its proprietary tests and pharmaceutical services.
Oncocyte Corporation has been recognized as one of the Top 5 Best Places to Work in Orange County for 2020, ranking 4th among medium-sized companies. This accolade, awarded by the Orange County Business Journal and Best Companies Group, evaluates workplace policies and employee experiences. With a commitment to delivering actionable insights in cancer care, Oncocyte emphasizes the importance of its talented, mission-driven team. This recognition highlights the company's growth potential in the molecular diagnostics industry.
Oncocyte Corporation (NYSE American: OCX) reports significant growth in testing volume for DetermaRx, its treatment stratification test for early-stage lung cancer. In Q3 2020, testing volume more than doubled to 175 samples, with a reorder rate of approximately 60%. Adoption has expanded to 67 hospitals, including NCCN and NCI centers, with international distribution initiated through an agreement with GenCell. The company anticipates continued growth through its other revenue streams, DetermaIO and Pharma Services, positioning it toward profitability.
Oncocyte Corporation (NYSE: OCX) announces that new data on DetermaRx™, a treatment stratification test for stage I-IIA non-small cell lung cancer (NSCLC), will be presented at the IASLC 2020 Conference on Lung Cancer. The study involved 250 patients, showing a 94% success rate in cancer-free patients opting for chemotherapy, while only 5% of low-risk patients faced recurrence. The integration of DetermaRx with EGFR mutation testing is set to commence this quarter, aiming to enhance treatment strategies. The data signifies DetermaRx’s rising adoption across hospitals and its reimbursement by Medicare.
Oncocyte Corporation (NYSE American: OCX) has announced a strategic collaboration with Fondazione Michelangelo to evaluate DetermaIO™ as a biomarker for response in triple-negative breast cancer (TNBC). This investigator-sponsored trial aims to generate short-term pharmaceutical services revenue and could support a U.S. clinical launch in late 2021. Initial studies suggest that DetermaIO outperforms existing biomarkers in predicting responses to PD-1 therapies. The partnership is part of Oncocyte's strategy to penetrate the ~$3B immunotherapy market, identifying eligible patients more accurately for treatment.
Oncocyte Corporation (NYSE American: OCX) announced that CEO Ronald Andrews and CMO Doug Ross will participate in the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference on September 17, 2020. The company focuses on molecular diagnostics to enhance cancer care, striving to improve patient outcomes. Recently, Oncocyte launched DetermaRx™, a test that identifies early-stage lung cancer patients at elevated risk for recurrence, and is developing DetermaIO™, a test for checkpoint immunotherapy responders.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What does Oncocyte Corporation specialize in?
What types of cancer does Oncocyte's diagnostics target?
What are some of Oncocyte's key products?
How does Oncocyte's DetermaIO™ test work?
What recent achievements has Oncocyte made?
Who are some of Oncocyte's partners?
What is the purpose of Oncocyte's VitaGraft™ test?
What is GraftAssure™ used for?
How does Oncocyte support its operations financially?
Where can I find more information about Oncocyte Corporation?
